Pharmaceutical company: AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), founded in 1981, headquartered in Waltham, Massachusetts, USA, with 552 full-time employees, is a professional pharmaceutical company focusing on providing products and services related to maternal health care, anemia management and cancer support treatment in the United States.

to update: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/amag-pharmaceuticals.html

On November 16, 2020, Covis Group S. à r.l. announced today that it had successfully bid for all outstanding shares of AMAG at a cash price of US $13.75 per share, completed the merger, and completed the acquisition of AMAG Pharmaceuticals, Inc. (formerly NASDAQ: AMAG). The merged organization will operate as part of Covis Pharma Group and will be led by Michael Porter, CEO of Covis. Covis' Headquartered in Luxembourg , with a business department in Zug, Switzerland, is a global specialty pharmaceutical company that provides treatment solutions for patients with life-threatening and chronic diseases. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/amag-pharmaceuticals.html

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/amag-pharmaceuticals.html

AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals is an American pharmaceutical company that develops iron deficiency anemia (IDA) products for adult patients and related intravenous drugs. AMAG Pharmaceuticals' business scope involves drug research and development, distribution and marketing, and its products are sold in the United States, Canada and Europe. AMAG Pharmaceuticals products include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/amag-pharmaceuticals.html

• Makena, a hydroxyprogesterone caproate injection, is used for pregnant women with a history of preterm birth to reduce the risk of preterm birth;
• Feraheme ® (ferumoxytol) Injection For Intravenous (IV) Use - an intravenous iron replacement therapy for injection, used to treat iron deficiency anemia in adult patients with chronic kidney disease. It was approved for listing by FDA in June 2009 and Health Canada in December 2011 for dialysis and non dialysis dependent chronic kidney disease patients, as well as for the treatment of iron deficiency anemia in adult patients. In August 2013, Ferumoxytol obtained the US patent certification, which will expire in 2020;
• MuGard ® Mucoadhesive Oral Wound Rinse - an oral wound cleaning product, used for oral mucositis, stomatitis and various oral wounds;
• In addition, AMAG Pharmaceutical Co., Ltd. provides cord blood storage services (in June 2015, AMAG acquired the Cord Blood Registry with US $700 million), including cord blood collection, processing, storage, registration, etc;
• AMZG Pharmaceuticals has a licensing agreement with Velo to obtain digoxin immune fab, a polyclonal antibody in the clinical development stage, for the treatment of severe preeclampsia in pregnant women.

AMAG Pharmaceuticals (AMAG) US equity investment

Due to acquisition Delisting ！ The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/amag-pharmaceuticals.html